Progress in molecular-based management of differentiated thyroid cancer.
Progress in molecular-based management of differentiated thyroid cancer.
复制标题
分化型甲状腺癌的分子治疗进展。
DOI：
10.1016/s0140-6736(13)60109-9
复制
发表时间：
2013-03-23
期刊：
影响因子：
168.9
通讯作者：
Schlumberger, Martin
中科院分区：
文献类型：
--
作者：
Xing, Mingzhao;Haugen, Bryan R.;Schlumberger, Martin
在过去的5-10年中，甲状腺癌的临床转化研究取得了实质性进展。诊断分子标记物，如RET-PTC，RAS和BRAFV 600 E突变;半乳糖凝集素3;和一种新的基因表达分类器，是改善甲状腺结节诊断的突出例子。BRAF突变是一种预后遗传标志物，可改善甲状腺癌患者的风险分层，因此可对甲状腺癌患者（包括传统低风险患者）进行量身定制的管理。如临床试验所示，新型分子靶向治疗对放射性碘难治性和手术不可手术的甲状腺癌有很大的希望;这种治疗可能在不久的将来成为甲状腺癌患者标准治疗方案的组成部分。这些新的基于分子的甲状腺结节和甲状腺癌管理策略是这个前所未有的甲状腺癌分子医学时代最令人兴奋的发展。
Substantial developments have occurred in the past 5–10 years in clinical translational research of thyroid cancer. Diagnostic molecular markers, such as RET-PTC, RAS, and BRAFV600E mutations; galectin 3; and a new gene expression classifier, are outstanding examples that have improved diagnosis of thyroid nodules. BRAF mutation is a prognostic genetic marker that has improved risk stratification and hence tailored management of patients with thyroid cancer, including those with conventionally low risks. Novel molecular-targeted treatments hold great promise for radioiodine-refractory and surgically inoperable thyroid cancers as shown in clinical trials; such treatments are likely to become a component of the standard treatment regimen for patients with thyroid cancer in the near future. These novel molecular-based management strategies for thyroid nodules and thyroid cancer are the most exciting developments in this unprecedented era of molecular thyroid-cancer medicine.